Hospital General Universitario Gregorio Marañón-ko ikertzaileekin lankidetzan egindako argitalpenak (20)

2023

  1. Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer

    Thrombosis Research, Vol. 232, pp. 133-137

2021

  1. Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications

    JCO oncology practice, Vol. 17, Núm. 8, pp. e1162-e1169

  2. Management and perception of therapeutic adherence of breakthrough cancer pain by oncologists in Spain

    Revista de la Sociedad Espanola del Dolor, Vol. 28, pp. 19-26

  3. Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study

    Frontiers in Oncology, Vol. 11

2020

  1. Breakthrough cancer pain: review and calls to action to improve its management

    Clinical and Translational Oncology, Vol. 22, Núm. 8, pp. 1216-1226

2019

  1. Active study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP)

    Clinical and Translational Oncology, Vol. 21, Núm. 3, pp. 380-390

  2. Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study)

    Lung Cancer, Vol. 135, pp. 161-168

  3. Working towards a consensus on the oncological approach of breakthrough pain: A Delphi survey of Spanish experts

    Journal of Pain Research, Vol. 12, pp. 2349-2358

2018

  1. Clinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii612

2016

  1. Controversies in the treatment of metastatic kidney cancer: A case report and review of the literature

    Cancer and Chemotherapy Reviews, Vol. 11, Núm. 1, pp. 3-11

  2. Quality indicators to assure and improve cancer care in Spain using the delphi technique

    JNCCN Journal of the National Comprehensive Cancer Network, Vol. 14, Núm. 5, pp. 553-558

  3. SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan

    Supportive Care in Cancer, Vol. 24, Núm. 1, pp. 499-507

2010

  1. Consensus document on the use of biosimilar granulocyte-colony stimulating factor for the correction of neutropenia associated in cancer patients

    Farmacia Hospitalaria, Vol. 34, Núm. SUPPL. 1, pp. 45-50

  2. Professional survey on knowledge and clinical patterns of pain management in Spanish medical oncology

    Clinical and Translational Oncology, Vol. 12, Núm. 12, pp. 819-824

2009

  1. Professional burnout among Spanish medical oncologists

    Clinical and Translational Oncology, Vol. 11, Núm. 2, pp. 86-90

2008

  1. Study of the prevalence of tumour-related asthenia in Spanish cancer patients

    Clinical and Translational Oncology, Vol. 10, Núm. 6, pp. 351-358

2006

  1. Polymorphisms in DNA repair genes modulate survival in cisplatin/ gemcitabine-treated non-small-cell lung cancer patients

    Annals of Oncology, Vol. 17, Núm. 4, pp. 668-675

  2. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: A Spanish Lung Cancer Group trial

    Annals of Oncology, Vol. 17, Núm. 3, pp. 467-472

2004

  1. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer

    Clinical Lung Cancer, Vol. 5, Núm. 6, pp. 360-365

2001

  1. Vinorelbine, ifosfamide and cisplatin as first-line treatment in patients with inoperable non-small cell lung cancer

    Lung Cancer, Vol. 34, Núm. 2, pp. 305-311